While the overall Neuromodulation Spinal Cord Stimulation (SCS) market continues to see strong, double-digit growth YTD, sequentially the US SCS market decelerated in Q317 due to seasonality and hurricane-related supply chain disruptions, particularly affecting Medtronic.
By Anne Staylor, Managing Editor, SmartTRAK Business Intelligence
YTD, the US SCS market is trending at high growth rates, a faster growth than SmartTRAK’s original 2017 forecast, as next generation products continue to drive unprecedented growth in this highly underpenetrated market. In the US, Abbott, Nevro and Boston Scientific’s (BSX) Q317 YoY SCS revenues increased respectively, while competitive pressures accelerated Medtronic’s US SCS revenue decline, down YoY according to SmartTRAK Financial Dashboard.
While the overall market continues to see strong, double-digit growth YTD, sequentially, the US SCS market decelerated in Q317. QoQ, US and WW SCS revenues were relatively flat due to seasonality and hurricane-related supply chain disruptions, particularly for Medtronic. Sequentially, Abbott, Boston Scientific and Nevro all gained share in Q317 to the detriment of Medtronic, which continues to lose share both in the US and WW. YoY, Medtronic’s US SCS market share is down in Q317 according to SmartTRAK Financial Dashboard. Abbott continued to outperform expectations with strong SCS revenue growth and share gains in Q317.
*This article can only be viewed by SmartTRAK subscribers to this module.